白云山:H股公告(至非登记股东之通知信函及回条-以电子方式发布公司通讯之安排)

(A joint stock company incorporated in the People’s Republic of China with limited liability)
（於中華人民共和國註冊成立之股份有限公司）
（H share Stock Code H股股份代碼：00874）
12 May 2025
Dear non-registered shareholder(s),
Arrangement of Electronic Dissemination of Corporate Communications
Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)
under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December
2023, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited. (the “Company”) is writing to inform you that the Company has
adopted electronic dissemination of corporate communications (the “Corporate Communications”), which means any documents issued or to be
issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its
annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where
applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.
Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of
the Company at www.gybys.com.cn, the company's third-party website at www.hmdatalink.com/C14070/tc/announcement.php and the
HKEXnews website at www.hkexnews.hk in place of printed copies. You need to proactively check the Company’s website and the HKEXnews
website to keep up with the publication of Corporate Communications.
You should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are
held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries.
If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the
Company’s Hong Kong share registrar (the “H Share Registrar”), Computershare Hong Kong Investor Services Limited , at 17M Floor, Hopewell
Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or send an email to Baiyunshan.ecom@computershare.com.hk specifying your name,
address and request to receive the Corporate Communications in printed form.
Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m.
to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.
The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited .
各位非登記股東：
以電子方式發布公司通訊之安排
根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下《香港聯合交易所有限公司證券上市規則》
（「上市規則」）第 2.07A 條，廣州白雲山醫藥集團股份有限公司（「公司」）謹此通知 閣下，公司已採用以電子方式發布公司通訊（「公司通訊」）之安排，該公司通訊是指公司為向其任何證券持有人提供信息或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a)董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b)中期報告及其中期報告摘要（如適用）；(c)
會議通知； (d) 上市文件； (e) 通函和 (f) 委任表格。
請 注 意 ， 所 有 未 來 公 司 通 訊 的 英 文 版 和 中 文 版 將 在 公 司 網 站 www.gybys.com.cn ， 公 司 第 三 方 網 站
www.hmdatalink.com/C14070/tc/announcement.php 和披露易網站 www.hkexnews.hk 上提供，以代替印刷本。 閣下需要主動查看公司網站和披露易網站以留意公司通訊的發布。
閣下應聯絡代 閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「中介公司」），並向 閣下的中介公司提供 閣下的電子郵件地址。
若 閣下希望收取公司通訊之印刷本，請填妥本函背頁之回條並交回公司的香港股份過戶登記處（「H 股股份登記處」）香港中央證券
登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓或發送電子郵件至 Baiyunshan.ecom@computershare.com.hk，並註
明 閣下的姓名、地址以及收取公司通訊印刷本的要求。
如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）期間致電 H 股
股份登記處(852) 2862 8688 查詢。
廣州白雲山醫藥集團股份有限公司
董事會
2025 年 5 月 12 日

CCS2475 GPCH _NRH
REPLY FORM 回條
To: Computershare Hong Kong Investor Services Limited 致： 香港中央證券登記有限公司
(The “H Share Registrar”) （「H 股股份登記處」）
17M Floor, Hopewell Centre, 香港灣仔皇后大道東 183 號
183 Queen’s Road East, Wanchai, Hong Kong 合和中心 17M 樓
REMINDER 提示
As a non-registered shareholder, you should liaise with your bank(s), broker(s), custodia